
Cogniguard
A breakthrough chapter in Alzheimer's treatment
The most promising treatment
for Alzheimer's disease
Based on patented non-invasive neuromodulation synchronized with brain's memory consolidation cycles
CLINICALLY TESTED ON PATIENTS WITH ALZHEIMER DISEASE
CERTIFIED FOR USE IN UE
EU-MDR
CE
2026 by Cogniguard Ltd. Confidential and Proprietary Information

Cogniguard

A breakthrough in Alzheimer's treatment

THE PROBLEM

As we live longer, Alzheimer is the defining health challenge of our generation.

12 MILLION

Over 12 million people in Western societies are living with Alzheimer's disease.

INSUFFICIENT TREATMENT

No effective treatment is currently available.

$14.5 TRILLION

The global economic burden of Alzheimer's is projected to exceed **$14.5 trillion by 2050**, far surpassing today's costs.

Cogniguard

A breakthrough in Alzheimer's treatment

THE SOLUTION

Vguard™

Non-invasive neurostimulation restoring memory during sleep.

Our core innovation is a **patented protocol of repetitive auricular vagus nerve stimulation** (VNS) delivered during natural sleep - the phase when memory consolidation is strongest.

SURPASSING DRUG EFFICIENCY

This enables a **+6 ADAS-Cog improvement** vs ≤2 points for the best available drugs.

PATENT PROTECTED

The technology is **protected by 6 patent families** and approved for sale **in Europe** (CE/MDR).

SCIENTIFIC FOUNDATION

10 years of neurophysiological research behind Vguard

Pre-clinical experiments on rat models confirmed that **auricular vagus nerve stimulation can induce hippocampal theta rhythm**.

This was the first documented case of **externally triggered theta activity** through peripheral stimulation.

We **published this in Brain Research** and form the basis of our **patented stimulation protocol.**

READ MORE



Theta oscillations (4–8 Hz) are essential for encoding and consolidating memories in the hippocampus. Loss of theta synchrony is one of the earliest biomarkers of Alzheimer's-related cognitive decline. **By restoring these natural rhythms, Vguard reactivates the brain's memory circuits - offering a fundamentally new therapeutic pathway.**

VALIDATION

Clinical results

Vguard's effectiveness was validated in two clinical trials.

Randomized, double-blind, placebo-controlled trial: **3-month nightly therapy with 51 patients in Poland and 15 in Israel**.

POLAND	Conducted with Medical University of Łódź, under Prof. Piotr Gałecki, **National Consultant in Psychiatry.**
ISRAEL	Conducted by Prof. Michael Davidson, at the **Israeli Alzheimer Center**.



Statistically significant improvement in cognitive function.

Group improved by +6 points ADAS-Cog
Safety: Well tolerated; minor headache (6%) and mild auricular irritation (6%).

THE IMPROVEMENT

What +6 ADAS-Cog really means for patients

The ADAS-Cog scale measures memory, attention, and verbal function in Alzheimer's patients **(0–70; higher = worse)**.

MARKET STANDARD

Standard drug treatments deliver **+1~2 points** of temporary improvement.

Cogniguard restores everyday autonomy, independence and dignity.



Cogniguard

A breakthrough in Alzheimer's treatment

GO TO MARKET

FDA approval unlocks access to €6B+ U.S. market and positions Cogniguard for strategic partnerships or acquisition.

PHASE 01 **2026-2027**

Multicenter clinical study

- **De-risking:** reproducing the results of the pilot clinical studies to prove that our method is scalable.
- Collecting data that will be necessary in the **reimbursement procedure.**
- Identification of the most responsive patients target group.
- The study on a group of **80-100 patients** in 3 centers.

Market readiness

PHASE 02 **2027-2028**

Reimbursement & European commercialization

- Launch reimbursement process via **national healthcare systems** (Germany, Poland).
- Expand through **memory clinic networks** and **telehealth providers**.
- **Scale manufacturing** under ISO13485 & MDR Class IIa certification.
- Build **medical awareness** through neurology & geriatric associations.

First revenues in Europe

PHASE 03 **2028+**

U.S. entry: global inflection point

- **FDA De Novo approval** using EU clinical data.
- **Full-speed commercialization:** Achieving high repeatable revenues from Europe and the US.
- **Strategic partnership** with global medtech (Philips / Medtronic / Abbott).

Expected revenues: **€ >45M** (Europe & USA)

THE TEAM

The core team operates between Israel and Poland, combining Israeli deep-tech innovation with European regulatory and clinical expertise.

Ehud Raivitz, MBA
Chief Executive Officer

Commercial leader. Former CEO of Elcam Medical, a global manufacturer of disposable medical devices with over 1,200 employees and $150M+ in annual revenues.

25+ years of experience in medtech and pharma operations.

Adam Broncel, M.D. Ph. D.
Chief Medical Officer

Neurologist with 20+ years of clinical and research experience in neurodegenerative disorders.

Expert in vagus nerve stimulation and neuroplasticity, co-author of multiple peer-reviewed studies on neuromodulation in Alzheimer's and epilepsy.

Magdalena Krawczyk, Ph. D.
Chief Psychologist Officer

Clinical Trials Coordinator with 16+ years of experience in psychology and cognitive-health research.

Leads Cogniguard's international clinical studies and development of innovative Alzheimer's therapies.

It is supported by 10 specialists in **engineering, clinical operations, and regulatory affairs**, and 5 world -renowned scientific and medical advisors.

Cogniguard

A breakthrough in Alzheimer's treatment

EXECUTIVE SUMMARY

FIRST ON MARKET	Cogniguard develops **the first non-invasive neuromodulation therapy** that restores cognitive function in early Alzheimer's disease.
PILOT STUDY	Studies at two independent centers (in Poland and Israel) **confirmed its effectiveness** (+6 ADAS-Cog improvement).
CE-CERTIFIED	This is the first and only **CE-certified** (Class IIa MDR) vagus nerve stimulation device in the world to date.
PATENTED	**6 Patent Families** covering core technology, various medical applications, special stimulation protocols, special electrodes configurations.
VALUATION INFLECTION POINT	Secure equity at a lower entry price **before the Series A round**, while benefiting from the major milestones already achieved.